Array BioPharma to Present Clinical Data at the 2008 Annual European Congress of Rheumatology

BOULDER, Colo.--(BUSINESS WIRE)--Jun 10, 2008 - Array BioPharma Inc. (Nasdaq: ARRY) today announced that clinical data will be presented on the MEK inhibitor, ARRY-162, and the pan-cytokine inhibitor, ARRY-797, at the 2008 Annual European Congress of Rheumatology in Paris, France. -0-
Title:       ARRY-162, a Novel Inhibitor of MEK Kinase: Phase 1a-1b

             Pharmacokinetic and Pharmacodynamic Results

             (Abstract: OP-0124)

Presenter:   John Yates, M.D., Chief Medical Officer, Array BioPharma

Date:        Thursday, June 12, 2008, 1:30 - 3:00 pm


Title:       ARRY-797, a Novel Inhibitor of p38 Map Kinase: Phase 1

             Pharmacokinetic and Pharmacodynamic Results

             (Abstract: THU0211)

Presenter:   Laura Carter, Research Investigator, Array BioPharma

Date:        Thursday, June 12, 2008, poster session


The presentation and poster will be available as PDFs after they are

presented on Array's website: www.arraybiopharma.com.

About ARRY-162 / Targeting MEK for Inflammation

MEK is an enzyme that regulates the biosynthesis of the inflammatory cytokines TNF, IL-6 and IL-1. Array scientists have discovered potent MEK inhibitors that interfere with these biosynthetic processes. We have previously advanced one MEK inhibitor, ARRY-886, into clinical development for the treatment of cancer. Given our experience with the safety profile of MEK inhibitors, we believe inhibition of MEK will have broad applications in diseases driven by IL-1 and TNF. ARRY-162, an orally active MEK inhibitor, has shown significant efficacy and is well tolerated in preclinical models of human arthritis and other inflammatory diseases.

About ARRY-797 / Pan-cytokine Inhibitor

ARRY-797 is a highly selective p38-alpha inhibitor, which modulates the production of several inflammatory mediators in human whole blood with nanomolar potency. ARRY-797 has unique properties, including high water solubility and tissue penetration, and was designed to limit distribution to the central nervous system.

About Array BioPharma:

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory diseases and pain. Our proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target proteins and are aimed at significant unmet medical needs. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. For more information on Array, please go to www.arraybiopharma.com.

Contact

Array BioPharma Inc.
Tricia Haugeto, 303-386-1193
ir@arraybiopharma.com

Posted: June 2008

View comments

Hide
(web4)